Valdoxan 유럽 연합 - 체코어 - EMA (European Medicines Agency)

valdoxan

les laboratoires servier - agomelatin - depresivní porucha, major - psychoanaleptics, - léčba depresivních epizod u dospělých.

Olysio 유럽 연합 - 체코어 - EMA (European Medicines Agency)

olysio

janssen-cilag international nv - simeprevir - hepatitida c, chronická - antivirotika pro systémové použití - přípravek olysio je indikován v kombinaci s jinými léčivými přípravky pro léčbu chronické hepatitidy c (chc) u dospělých pacientů. pro virus hepatitidy c (hcv) genotypu konkrétní činnosti.

Orphacol 유럽 연합 - 체코어 - EMA (European Medicines Agency)

orphacol

theravia - kyselina cholová - digestive system diseases; metabolism, inborn errors - Žlučové kyseliny a jejich deriváty - přípravek orphacol je indikován k léčbě vrozených poruch v primární syntézy žlučových kyselin v důsledku 3β-hydroxy-Δ5-c27-steroid oxidoreduktázy nedostatek nebo Δ4 – 3 – oxosteroid – 5β – reduktázy methylacyl děti a dospívající ve věku od jednoho měsíce do 18 let a dospělí.

Sarclisa 유럽 연합 - 체코어 - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - mnohočetný myelom - antineoplastická činidla - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Carvykti 유럽 연합 - 체코어 - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Enjaymo 유럽 연합 - 체코어 - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresiva - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Plerixafor Accord 유럽 연합 - 체코어 - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - imunostimulancia, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Slape® Trio 체코 - 체코어 - Adama

slape® trio

adama - emulgovatelný koncentrát - prothioconazole + spiroxamin + tebuconazole - fungicidy

ALKERAN 50MG Prášek a rozpouštědlo pro injekční/infuzní roztok 체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

alkeran 50mg prášek a rozpouštědlo pro injekční/infuzní roztok

aspen pharma trading limited, dublin array - 1571 melfalan - prášek a rozpouštědlo pro injekční/infuzní roztok - 50mg - melfalan

LeukoScan 유럽 연합 - 체코어 - EMA (European Medicines Agency)

leukoscan

immunomedics gmbh - sulesomab - osteomyelitis; radionuclide imaging - diagnostické prostředky - tento léčivý přípravek je určen pouze pro diagnostické účely. leukoscan je indikován pro diagnostické zobrazovací metody pro určení místa a rozsahu infekce nebo zánětu v kosti u pacientů s podezřením na osteomyelitidu, včetně pacientů s vředy na diabetické noze. leukoscan nebyl zaměstnán na diagnostice osteomyelitidy u pacientů se srpkovitou anémií.